Pasithea Therapeutics Corp. Share Price
NASDAQ: KTTA | Micro CapPasithea Therapeutics Corp. Stock Performance
Open $0.51 | Prev. Close $0.51 | Circuit Range N/A |
Day Range $0.48 - $0.52 | Year Range $0.29 - $2.06 | Volume 2,935 |
Average Traded $0.51 |
Pasithea Therapeutics Corp. Share Price Today
As of 11 August 2026, Pasithea Therapeutics Corp.'s share price is $0.48. The stock opened at $0.51, compared to its previous close of $0.51. During today's trading session, Pasithea Therapeutics Corp.'s share price traded between $0.48 and $0.52, with an average price of $0.50. Over the past 52 weeks, the stock has recorded a high of $2.06 and a low of $0.29. In terms of performance, Pasithea Therapeutics Corp.'s share price has declined by 40.99% over the last six months and is down 40.33% on a year-on-year basis.
Pasithea Therapeutics Corp. Share Price Chart
Pasithea Therapeutics Corp. Stock Fundamentals & Key Indicators
Market Cap $3.40M | PE Ratio (TTM) -0.17 | Dividend Yield N/A |
EPS (TTM) $-2.91 | Revenue (TTM) N/A | Return On Equity (TTM) -36.99% |
Profit Margin N/A | Debt to Equity 0.09 | Quarterly Earnings Growth YoY -1.25% |
Pasithea Therapeutics Corp. Quarterly Profit & Loss
All figures in USD
Pasithea Therapeutics Corp. Annual Profit & Loss
All figures in USD
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Pasithea Therapeutics Corp. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.45 | $0.48 | +3.87% |
Jul 2026 | $0.59 | $0.47 | -9.36% |
Jun 2026 | $0.71 | $0.51 | -27.85% |
May 2026 | $0.72 | $0.71 | +0.71% |
Apr 2026 | $0.65 | $0.71 | -5.87% |
Mar 2026 | $0.83 | $0.75 | -8.42% |
Feb 2026 | $0.85 | $0.82 | -4.99% |
Jan 2026 | $1.23 | $0.86 | -33.69% |
Dec 2025 | $1.25 | $1.30 | -10.96% |
Nov 2025 | $0.82 | $1.46 | +82.27% |
Oct 2025 | $0.73 | $0.80 | +11.25% |
Sep 2025 | $0.81 | $0.72 | -11.11% |